Dendritic Cells for Cancer Immunotherapy

Scientists at NCCS have developed a novel two-step method for large-scale generation of mature, functional Dendritic Cells (DC) from Umbilical cord blood (UCB). This technology will aid in development of dendritic cell based vaccines for cancer immunotherapy. Unlike conventional method of generating DCs, which uses peripheral blood (PBL) monocytes, this technology enables use of allogeneic sources like stem cells (CD34+) as well as mononuclear cells (MNCs) isolated from umbilical cord blood (UCB).

dendritic cells

Technology Readiness: TRL B1 (In-vitro efficacy/ results demonstrated)

Technology Status: Proprietary know-how

Technology Availability: Know-how available for transfer and/or co-development with partners.


  1. A simple two-step culture system for the large-scale generation of mature and functional dendritic cells from umbilical cord blood CD34+ cells, Transfusion 2009; 49:2109-2121 (Article).
  2. Exogenous Addition of Arachidonic Acid to the Culture Media Enhances the Functionality of Dendritic Cells for Their Possible Use in Cancer Immunotherapy, PlosOne Nov 2014, Vol 9:11 (Article).
  3. Umbilical cord blood-derived CD11c+ dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy, Stem Cell Research & Therapy (2015) 6:184 (Article).
  4. A large number of mature and functional dendritic cells can be efficiently generated from umbilical cord blood–derived mononuclear cells by a simple two-step culture method, Transfusion 2010, 50:2413-2423 (Article).